Ona says more than half of ONA-255 Phase 1a patients enrolled
AI Summary- Ona Therapeutics has enrolled more than half of participants planned for the ONA-255 Phase 1a study.
- More than half of planned patients are enrolled as ONA-255 continues dose escalation.
- Aleix Prat became Chief Medical Officer, while Jutta Amersdorffer became Chief Development Officer.